Haisco Pharmaceutical Group Co., Ltd.
002653
주식 순위
#2011
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
주가
$9.03
시가총액
$10.30B
변동 (1일)
4.55%
변동 (1년)
24.15%
국가
CN
거래 Haisco Pharmaceutical Group Co., Ltd. (002653)
카테고리
Healthcare
Haisco Pharmaceutical Group Co., Ltd. (002653)의 매출
Jun 2026 기준 매출 TTM: $794.50M
Haisco Pharmaceutical Group Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $794.50M입니다. 2023년에 회사는 $473.97M의 수익을 올렸으며 이는 2022년의 $437.13M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Haisco Pharmaceutical Group Co., Ltd.의 수익 기록 (2008 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $794.50M | 55.83% |
| 2024 | $509.84M | 7.57% |
| 2023 | $473.97M | 8.43% |
| 2022 | $437.13M | 0.18% |
| 2021 | $436.34M | -14.39% |
| 2020 | $509.68M | -9.86% |
| 2019 | $565.44M | 13.51% |
| 2018 | $498.16M | 74.62% |
| 2017 | $285.29M | 37.97% |
| 2016 | $206.77M | 10.75% |
| 2015 | $186.71M | -4.47% |
| 2014 | $195.45M | 19.47% |
| 2013 | $163.60M | 27.19% |
| 2012 | $128.62M | 34.15% |
| 2011 | $95.88M | 8.81% |
| 2010 | $88.11M | 24.14% |
| 2009 | $70.98M | 36.50% |
| 2008 | $52.00M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 1,488.97% |
US
|
|
| $2.23B | 180.43% |
US
|
|
| $15.74B | 1,881.68% |
AU
|
|
| $6.02B | 657.88% |
NL
|
|
| - | - |
CH
|
